Skip to main content

Articles

316 result(s) for 'serum psa 29' within BMC Cancer

Page 2 of 7

  1. The expression status of apoptotic regulators, such as caspases and inhibitors of apoptosis proteins (IAPs), could reflect the aggressiveness of tumors and, therefore, could be useful as prognostic markers. We...

    Authors: Gonzalo Rodríguez-Berriguete, Norelia Torrealba, Miguel Angel Ortega, Pilar Martínez-Onsurbe, Gabriel Olmedilla, Ricardo Paniagua, Manuel Guil-Cid, Benito Fraile and Mar Royuela
    Citation: BMC Cancer 2015 15:809
    Content type: Research article Published on:

  2. Gamma-synuclein (SNCG) has previously been demonstrated to be significantly correlated with metastatic malignancies; however, in-depth investigation of SNCG in prostate cancer is still lacking. In the present ...

    Authors: Junyi Chen, Li Jiao, Chuanliang Xu, Yongwei Yu, Zhensheng Zhang, Zheng Chang, Zhen Deng and Yinghao Sun
    Citation: BMC Cancer 2012 12:593
    Content type: Research article Published on:

  3. Androgen receptor (AR) signalling is critical to the initiation and progression of prostate cancer (PCa). Transcriptional activity of AR involves chromatin recruitment of co-activators, including the p300/CBP-...

    Authors: Ai-Yu Gong, Alex N Eischeid, Jing Xiao, Jian Zhao, Dongqing Chen, Zhao-Yi Wang, Charles YF Young and Xian-Ming Chen
    Citation: BMC Cancer 2012 12:492
    Content type: Research article Published on:

  4. Identifying cellular signaling pathways that become corrupted in the presence of androgens that increase the metastatic potential of organ-confined tumor cells is critical to devising strategies capable of att...

    Authors: Jordy J Hsiao, Brandon H Ng, Melinda M Smits, Jiahui Wang, Rohini J Jasavala, Harryl D Martinez, Jinhee Lee, Jhullian J Alston, Hiroaki Misonou, James S Trimmer and Michael E Wright
    Citation: BMC Cancer 2015 15:204
    Content type: Research article Published on:

  5. Salvage radiotherapy (SRT) for prostate cancer (PCa) recurrence after prostatectomy offers long-term biochemical control in about 50–60% of patients. SRT is commonly initiated in patients with serum PSA levels...

    Authors: Jeremie Calais, Johannes Czernin, Wolfgang P. Fendler, David Elashoff and Nicholas G. Nickols
    Citation: BMC Cancer 2019 19:18
    Content type: Study protocol Published on:

    The Correction to this article has been published in BMC Cancer 2019 19:97

  6. We describe a randomized, non-blinded Phase II interventional study to assess the safety and efficacy of stereotactic ablative radiotherapy (SABR) for hormone-sensitive oligometastatic prostate adenocarcinoma,...

    Authors: Noura Radwan, Ryan Phillips, Ashley Ross, Steven P. Rowe, Michael A. Gorin, Emmanuel S. Antonarakis, Curtiland Deville, Stephen Greco, Samuel Denmeade, Channing Paller, Daniel Y. Song, Maximilian Diehn, Hao Wang, Michael Carducci, Kenneth J. Pienta, Martin G. Pomper…
    Citation: BMC Cancer 2017 17:453
    Content type: Study protocol Published on:

  7. Recruitment of cofactors in the interaction of the androgen receptor (AR) and AR ligands plays a critical role in determining androgenic/antiandrogenic effects of the AR ligand on signaling, but the functions ...

    Authors: Keisuke Takeda, Noboru Hara, Tsutomu Nishiyama, Masayuki Tasaki, Fumio Ishizaki and Yoshihiko Tomita
    Citation: BMC Cancer 2016 16:332
    Content type: Research article Published on:

  8. In recent years, there is increasing evidence showing a beneficial outcome (e.g. progression free survival; PFS) after metastases-directed therapy (MDT) with external beam radiotherapy (EBRT) or targeted surge...

    Authors: Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Michel de Groot, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel…
    Citation: BMC Cancer 2020 20:884
    Content type: Study protocol Published on:

    The Update to this article has been published in Trials 2021 22:768

  9. The routine clinical use of serum prostatic specific antigen (PSA) testing has allowed earlier detection of low-grade prostate cancer (PCa) with more favourable characteristics, leading to increased acceptance...

    Authors: Salonee Shah, Kerri Beckmann, Mieke Van Hemelrijck, Ben Challacombe, Rick Popert, Prokar Dasgupta, Jonah Rusere, Grace Zisengwe, Oussama Elhage and Aida Santaolalla
    Citation: BMC Cancer 2021 21:573
    Content type: Database Published on:

    The Correction to this article has been published in BMC Cancer 2022 22:97

  10. The purpose of this study was to evaluate the role of osteoprotegerin gene (OPG) polymorphisms as genetic modifiers in the etiology of prostate cancer (PCa) and disease progression.

    Authors: Naofumi Narita, Takeshi Yuasa, Norihiko Tsuchiya, Teruaki Kumazawa, Shintaro Narita, Takamitsu Inoue, Zhiyong Ma, Mitsuru Saito, Yohei Horikawa, Shigeru Satoh, Osamu Ogawa and Tomonori Habuchi
    Citation: BMC Cancer 2008 8:224
    Content type: Research article Published on:

  11. The neutrophil-to-lymphocyte ratio (NLR), a simple marker of the systemic inflammatory response in critical care patients, has been suggested as an independent prognostic factor for several solid malignancies....

    Authors: Takashi Kawahara, Yumiko Yokomizo, Yusuke Ito, Hiroki Ito, Hitoshi Ishiguro, Jun-ichi Teranishi, Kazuhide Makiyama, Yasuhide Miyoshi, Hiroshi Miyamoto, Masahiro Yao and Hiroji Uemura
    Citation: BMC Cancer 2016 16:111
    Content type: Research article Published on:

  12. Platelet to Lymphocyte ratio (PLR) is thought to be associated with a worse outcome in multiple types of cancer. However, the prognostic significance of PLR has not been investigated in the prostate cancer (PC...

    Authors: Yanqing Wang, Fan Xu, Jiahua Pan, Yinjie Zhu, Xiaoguang Shao, Jianjun Sha, Zezhou Wang, Yong Cai, Qiang Liu, Baijun Dong, Wei Xue and Yiran Huang
    Citation: BMC Cancer 2016 16:329
    Content type: Research article Published on:

  13. Currently, there are no satisfactory biomarkers available to screen for diffuse large B cell lymphoma (DLBCL) or to identify patients who do not benefit from standard anti-cancer therapies. In this study, we u...

    Authors: Xing Zhang, Bo Wang, Xiao-shi Zhang, Zhi-ming Li, Zhong-zhen Guan and Wen-qi Jiang
    Citation: BMC Cancer 2007 7:235
    Content type: Research article Published on:

  14. Little is known about the relationship between the metabolite profile of plasma from pre-operative prostate cancer (PCa) patients and the risk of PCa progression. In this study we investigated the association ...

    Authors: Eugenio Zoni, Martina Minoli, Cédric Bovet, Anne Wehrhan, Salvatore Piscuoglio, Charlotte K. Y. Ng, Peter C. Gray, Martin Spahn, George N. Thalmann and Marianna Kruithof-de Julio
    Citation: BMC Cancer 2019 19:1216
    Content type: Research article Published on:

  15. C4-2 prostate cancer (CaP) cells grown in mouse tibiae cause a mixed osteoblastic/osteolytic response with increases in osteoclast numbers and bone resorption. Administration of osteoprotegerin (OPG) blocks th...

    Authors: Colm Morrissey, Paul L Kostenuik, Lisha G Brown, Robert L Vessella and Eva Corey
    Citation: BMC Cancer 2007 7:148
    Content type: Research article Published on:

  16. Pelvic lymph nodes removed during radical retropubic prostatectomy for prostatic cancer can be found on pathological examination to harbor various unexpected pathologies. Among these, hematologic neoplasms are...

    Authors: Antonio Di Meglio, Pier Vitale Nuzzo, Francesco Ricci, Bruno Spina and Francesco Boccardo
    Citation: BMC Cancer 2014 14:613
    Content type: Case report Published on:

  17. Several predisposition loci for hereditary prostate cancer (HPC) have been suggested, including HPCX1 at Xq27-q28, but due to the complex structure of the region, the susceptibility gene has not yet been identifi...

    Authors: Henna Mattila, Martin Schindler, Jarkko Isotalo, Tarja Ikonen, Mauno Vihinen, Hannu Oja, Teuvo LJ Tammela, Tiina Wahlfors and Johanna Schleutker
    Citation: BMC Cancer 2011 11:327
    Content type: Research article Published on:

  18. Neoadjuvant androgen deprivation therapy (ADT) has been suggested to confer several clinical benefits in patients with prostate cancer (PCa) undergoing transperineal prostate brachytherapy (TPPB). Unlike gonad...

    Authors: Kenta Miki, Hiroshi Sasaki, Masahito Kido, Hiroyuki Takahashi, Manabu Aoki and Shin Egawa
    Citation: BMC Cancer 2016 16:708
    Content type: Study protocol Published on:

  19. The aim of this prospective phase II study was to evaluate the efficacy and safety of biweekly docetaxel plus androgen-deprivation therapy (ADT) in patients with metastatic castration-naïve prostate cancer (mC...

    Authors: Seonggyu Byeon, Hongsik Kim, Hwang Gyun Jeon, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Soon Il Lee and Se Hoon Park
    Citation: BMC Cancer 2021 21:1281
    Content type: Research Published on:

  20. The bone scan index (BSI) using a computer-aided diagnosis system for bone scans is expected to be an objective and quantitative clinical tool for evaluating bone metastatic prostate cancer. This study aimed t...

    Authors: Yasuhide Miyoshi, Shuko Yoneyama, Takashi Kawahara, Yusuke Hattori, Jun-ichi Teranishi, Keiichi Kondo, Masatoshi Moriyama, Shigeo Takebayashi, Yumiko Yokomizo, Masahiro Yao, Hiroji Uemura and Kazumi Noguchi
    Citation: BMC Cancer 2016 16:128
    Content type: Research article Published on:

  21. Whether chronic inflammation increases prostate cancer risk remains unclear. This study investigated whether chronic inflammatory diseases (CID) or anti-inflammatory medication use (AIM) were associated with p...

    Authors: Kerri Beckmann, Beth Russell, Debra Josephs, Hans Garmo, Christel Haggstrom, Lars Holmberg, Pär Stattin, Mieke Van Hemelrijck and Jan Adolfsson
    Citation: BMC Cancer 2019 19:612
    Content type: Research article Published on:

  22. Prostate cancer (PCa) is the most common non-skin cancer in USA and the second leading cause of cancer death in Western Countries. Despite the high mortality associated with PCa, the only established risk fact...

    Authors: Cosimo De Nunzio, Giuseppe Simone, Aldo Brassetti, Riccardo Mastroianni, Devis Collura, Giovanni Muto, Michele Gallucci and Andrea Tubaro
    Citation: BMC Cancer 2016 16:407
    Content type: Research article Published on:

  23. There is no biological or epidemiological data on the association between NOS3 promoter polymorphisms and prostate cancer. The polymorphisms in the promoter region of NOS3 gene may be responsible for variations i...

    Authors: Karina Marangoni, Thaíse G Araújo, Adriana F Neves and Luiz R Goulart
    Citation: BMC Cancer 2008 8:273
    Content type: Research article Published on:

  24. Expression of the androgen receptor (AR) is associated with androgen-dependent proliferation arrest and terminal differentiation of normal prostate epithelial cells. Additionally, activation of the AR is requi...

    Authors: Jan Roger Olsen, Waqas Azeem, Margrete Reime Hellem, Kristo Marvyin, Yaping Hua, Yi Qu, Lisha Li, Biaoyang Lin, XI-Song Ke, Anne Margrete Øyan and Karl-Henning Kalland
    Citation: BMC Cancer 2016 16:377
    Content type: Research article Published on:

  25. To investigate the predictive value of metabolic syndrome (MetS) and its components in biochemical recurrence (BCR) and adverse pathological features of patients with prostate cancer (PCa) after radical prosta...

    Authors: Zenan Liu, Xuehua Zhu, Jide He and Jian Lu
    Citation: BMC Cancer 2023 23:50
    Content type: Research Published on:

  26. Several bone-seeking radionuclides have been developed for palliation of metastatic bone pain since 1956, however, so far radium-223 dichloride is the first and only Food and Drug Administration (FDA) approved...

    Authors: Zin W. Myint, Riham El Khouli, Bryan Lemieux, Donglin Yan, William H. St. Clair, Xiaoqi Liu and Charles A. Kunos
    Citation: BMC Cancer 2022 22:415
    Content type: Study protocol Published on:

  27. Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2–3 years. A subgroup of those patients with mC...

    Authors: Charlien Berghen, Steven Joniau, Kato Rans, Gaëtan Devos, Kenneth Poels, Koen Slabbaert, Herlinde Dumez, Maarten Albersen, Karolien Goffin, Karin Haustermans and Gert De Meerleer
    Citation: BMC Cancer 2020 20:457
    Content type: Study protocol Published on:

  28. Although bone marrow metastases can be found commonly in some malignant tumors, diagnosing a nonhematologic malignancy from marrow is not a usual event.

    Authors: Fahir Ozkalemkas, Rıdvan Ali, Vildan Ozkocaman, Tulay Ozcelik, Ulku Ozan, Hulya Ozturk, Ender Kurt, Turkkan Evrensel, Omer Yerci and Ahmet Tunali
    Citation: BMC Cancer 2005 5:144
    Content type: Research article Published on:

  29. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers. However, no reliable biomarker of survival or response has entered the clinic to identify those patients wit...

    Authors: Alessia Visconti, Niccolò Rossi, Helena Deriš, Karla A Lee, Maja Hanić, Irena Trbojević-Akmačić, Andrew M. Thomas, Laura A. Bolte, Johannes R. Björk, Jahlisa S. Hooiveld-Noeken, Ruth Board, Mark Harland, Julia Newton-Bishop, Mark Harries, Joseph J. Sacco, Paul Lorigan…
    Citation: BMC Cancer 2023 23:166
    Content type: Research Published on:

  30. Prognostic multibiomarker signatures in prostate cancer (PCa) may improve patient management and provide a bridge for developing novel therapeutics and imaging methods. Our objective was to evaluate the associ...

    Authors: Anthony E Rizzardi, Nikolaus K Rosener, Joseph S Koopmeiners, Rachel Isaksson Vogel, Gregory J Metzger, Colleen L Forster, Lauren O Marston, Jessica R Tiffany, James B McCarthy, Eva A Turley, Christopher A Warlick, Jonathan C Henriksen and Stephen C Schmechel
    Citation: BMC Cancer 2014 14:244
    Content type: Research article Published on:

  31. With the recent introduction of novel treatment options, real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) are required to better understand the impact on routine clini...

    Authors: Martin Boegemann, Sara Khaksar, Guillaume Bera, Alison Birtle, Catherine Dopchie, Louis-Marie Dourthe, Els Everaert, Martin Hatzinger, Dirko Hercher, Werner Hilgers, Geoffrey Matus, Laura Garcia Alvarez, Laurent Antoni, Martin Lukac, Geneviève Pissart, Paul Robinson…
    Citation: BMC Cancer 2019 19:60
    Content type: Research article Published on:

  32. Although chemotherapy for prostate cancer (PCa) can improve patient survival, some tumours are chemo-resistant. Tumour molecular profiles may help identify the mechanisms of drug action and identify potential ...

    Authors: Prabhakar Rajan, Jacqueline Stockley, Ian M Sudbery, Janis T Fleming, Ann Hedley, Gabriela Kalna, David Sims, Chris P Ponting, Andreas Heger, Craig N Robson, Rhona M McMenemin, Ian D Pedley and Hing Y Leung
    Citation: BMC Cancer 2014 14:977
    Content type: Research article Published on:

  33. Expression of periostin is an indicator of epithelial-mesenchymal transition in cancer but a detailed analysis of periostin expression in prostate cancer has not been conducted so far.

    Authors: Verena Tischler, Florian R Fritzsche, Peter J Wild, Carsten Stephan, Hans-Helge Seifert, Marc-Oliver Riener, Thomas Hermanns, Ashkan Mortezavi, Josefine Gerhardt, Peter Schraml, Klaus Jung, Holger Moch, Alex Soltermann and Glen Kristiansen
    Citation: BMC Cancer 2010 10:273
    Content type: Research article Published on:

  34. African Americans have disproportionately higher burden of prostate cancer compared to European Americans. However, the cause of prostate cancer disparities is still unclear. Several roles have been proposed f...

    Authors: Ken Batai, Adam B. Murphy, Maria Ruden, Jennifer Newsome, Ebony Shah, Michael A. Dixon, Elizabeth T. Jacobs, Courtney M. P. Hollowell, Chiledum Ahaghotu and Rick A. Kittles
    Citation: BMC Cancer 2017 17:64
    Content type: Research article Published on:

  35. The optimal protocol for 125I-transperineal prostatic brachytherapy (TPPB) in intermediate-risk prostate cancer (PCa) patients remains controversial. Data on the efficacy of combining androgen-deprivation therapy...

    Authors: Kenta Miki, Takayoshi Kiba, Hiroshi Sasaki, Masahito Kido, Manabu Aoki, Hiroyuki Takahashi, Keiko Miyakoda, Takushi Dokiya, Hidetoshi Yamanaka, Masanori Fukushima and Shin Egawa
    Citation: BMC Cancer 2010 10:572
    Content type: Study protocol Published on:

  36. Second-generation androgen receptor inhibitors (ARIs) have been associated with adverse events (AEs) such as fatigue, falls, fractures, and rash in non-metastatic castration-resistant prostate cancer (nmCRPC) ...

    Authors: Arif Hussain, Shan Jiang, Della Varghese, Sreevalsa Appukkuttan, Nehemiah Kebede, Kajan Gnanasakthy, Cynthia Macahilig, Reg Waldeck and Shelby Corman
    Citation: BMC Cancer 2022 22:304
    Content type: Research Published on:

  37. Pelvic nodal recurrences are being increasingly diagnosed with the introduction of new molecular imaging techniques, like choline and PSMA PET-CT, in the restaging of recurrent prostate cancer (PCa). At this m...

    Authors: A. De Bruycker, A. Spiessens, P. Dirix, N. Koutsouvelis, I. Semac, N. Liefhooghe, A. Gomez-Iturriaga, W. Everaerts, F. Otte, A. Papachristofilou, M. Scorsetti, M. Shelan, S. Siva, F. Ameye, M. Guckenberger, R. Heikkilä…
    Citation: BMC Cancer 2020 20:406
    Content type: Study protocol Published on:

  38. Androgen deprivation therapy (ADT) combined with docetaxel chemotherapy is the standard treatment for metastatic castration-resistant prostate cancer (mCRPC) patients. However, mCRPC patients are mainly frail ...

    Authors: Xiangwei Yang, Hong Chen, Duanya Xu, Xianju Chen, Yamei Li, Jun Tian, Dongwen Wang and Jun Pang
    Citation: BMC Cancer 2022 22:177
    Content type: Study protocol Published on:

  39. We analyzed the relationship between prostate cancer outcomes and pretreatment clinical factors and developed a prognostic nomogram of overall survival (OS) of patients with bone metastasis.

    Authors: Yasuhide Miyoshi, Kazumi Noguchi, Masahiro Yanagisawa, Masataka Taguri, Satoshi Morita, Ichiro Ikeda, Kiyoshi Fujinami, Takeshi Miura, Kazuki Kobayashi and Hiroji Uemura
    Citation: BMC Cancer 2015 15:338
    Content type: Research article Published on:

  40. The selection of patients according to key genetic characteristics may help to tailor chemotherapy and optimize the treatment in Castration-Resistant Prostate Cancer (CRPC) patients. Functional polymorphisms w...

    Authors: Ilaria Pastina, Elisa Giovannetti, Aldo Chioni, Tristan M Sissung, Francesco Crea, Cinzia Orlandini, Douglas K Price, Claudia Cianci, William D Figg, Sergio Ricci and Romano Danesi
    Citation: BMC Cancer 2010 10:511
    Content type: Research article Published on:

  41. Advances in molecular biology and growing requirements from biomarker validation studies have generated a need for tissue banks to provide quality-controlled tissue samples with standardized clinical annotatio...

    Authors: Ashokkumar A Patel, John R Gilbertson, Anil V Parwani, Rajiv Dhir, Milton W Datta, Rajnish Gupta, Jules J Berman, Jonathan Melamed, Andre Kajdacsy-Balla, Jan Orenstein and Michael J Becich
    Citation: BMC Cancer 2006 6:120
    Content type: Research article Published on:

  43. Coactivator-associated arginine methyltransferase 1 (CARM1) functions as a transcriptional coactivator of androgen receptor (AR)-mediated signaling. Correspondingly, overexpression of CARM1 has been associated...

    Authors: Young-Rang Kim, Byung Kook Lee, Ra-Young Park, Nguyen Thi Xuan Nguyen, Jeong A Bae, Dong Deuk Kwon and Chaeyong Jung
    Citation: BMC Cancer 2010 10:197
    Content type: Research article Published on:

  44. Orthotopic LNCaP xenograft mouse models closely mimic the progression of androgen-dependent prostate cancer in humans; however, orthotopic injection of LNCaP cells into the mouse prostate remains a challenge.

    Authors: Weiyong Liu, Yunkai Zhu, Lei Ye, Yajuan Zhu and Yuhao Wang
    Citation: BMC Cancer 2022 22:173
    Content type: Research Published on:

    The Correction to this article has been published in BMC Cancer 2022 22:200

  45. A computer-assisted diagnostic system for analyzing bone scans (BONENAVI) calculates the automated bone scan index (aBSI). Here we evaluated the aBSI as a prognostic imaging biomarker for men with metastatic c...

    Authors: Koichi Uemura, Yasuhide Miyoshi, Takashi Kawahara, Jikuya Ryosuke, Daisuke Yamashita, Shuko Yoneyama, Yumiko Yokomizo, Kazuki Kobayashi, Takeshi Kishida, Masahiro Yao and Hiroji Uemura
    Citation: BMC Cancer 2018 18:501
    Content type: Research article Published on:

  46. Metastasis-directed therapy (MDT) significantly delays the initiation of palliative androgen deprivation therapy (pADT) in patients with oligorecurrent prostate cancer (PCa) with a positive impact on patient’s...

    Authors: Kato Rans, Berghen Charlien, Ameye Filip, De Hertogh Olivier, den Hartog Julie, Draulans Céderic, Dumez Herlinde, Engels Benedikt, Goffin Karolien, Laenen Annouschka, Liefhooghe Nick, Poels Kenneth, Salembier Carl, Slabbaert Koen, Vandendriessche Hans, Vanneste Ben…
    Citation: BMC Cancer 2022 22:1294
    Content type: Study protocol Published on:

  47. High serum carcinoembryonic antigen (CEA) levels are an independent prognostic factor for recurrence and survival in patients with non-small cell lung cancer (NSCLC). Its role as a predictive marker of treatme...

    Authors: Oscar Arrieta, Cynthia Villarreal-Garza, Luis Martínez-Barrera, Marcelino Morales, Yuzmiren Dorantes-Gallareta, Omar Peña-Curiel, Susana Contreras-Reyes, Eleazar Omar Macedo-Pérez and Jorge Alatorre-Alexander
    Citation: BMC Cancer 2013 13:254
    Content type: Research article Published on:

  48. To assess the diagnostic performance of a panel of standard tumor markers (TMs) in patients hospitalized with significant involuntary weight loss (IWL) and elevated levels of inflammation biomarkers, and a com...

    Authors: Morgane Gronnier, Kaies Hedhli, Chloé Sauzay, Valéry Salle, Pierre Duhaut, Jean Schmidt and Amandine Dernoncourt
    Citation: BMC Cancer 2024 24:468
    Content type: Research Published on:

  49. A new 5-tiered grading grouping system has recently been endorsed for reporting of prostate cancer (PCa) grade to better reflect escalating risk of progression and cancer death. While several validations of th...

    Authors: K. R. Beckmann, A. D. Vincent, M. E. O’Callaghan, P. Cohen, S. Chang, M. Borg, S. M. Evans, D. M. Roder and K. L. Moretti
    Citation: BMC Cancer 2017 17:537
    Content type: Research article Published on:

  50. Metastatic prostate cancer remains a common cause of death in Europe, and improvements in management of the disease are urgently needed. The advent of positron-emission tomography (PET) imaging enhanced with f...

    Authors: Stephane Supiot, Emmanuel Rio, Valérie Pacteau, Marie-Hélène Mauboussin, Loïc Campion and François Pein
    Citation: BMC Cancer 2015 15:646
    Content type: Study protocol Published on:

Featured videos

View featured videos from across the BMC-series journals

Submit manuscript

Follow

BMC Cancer

ISSN: 1471-2407

Contact us